Literature DB >> 21908058

Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.

Akira Matsuda1, Akane Tanaka, Yosuke Amagai, Keitaro Ohmori, Sho Nishikawa, Yan Xia, Kaoru Karasawa, Noriko Okamoto, Kumiko Oida, Hyosun Jang, Hiroshi Matsuda.   

Abstract

Glucocorticoid (GC) administration with or without other chemotherapeutic reagents is a commonly used option in the treatment of mast cell malignancies. However, the responsiveness of mast cell tumors to GC treatment varies in individuals, and the regulatory mechanisms determining the GC sensitivity of malignant mast cells remain unclear. Since the expression of the GC receptor (GR) has been reported to be associated with GC sensitivity in human neoplastic lymphocytes, we attempted to investigate the relationship between GR levels and GC sensitivity by using neoplastic mast cells derived from canine mast cell tumors (MCTs). To elucidate the regulatory mechanisms involved in GC responsiveness, we analyzed various canine MCT cell lines and tissue samples from dogs with MCT. While the proliferation of canine MCT cells was suppressed by the addition of GC to the culture, we found that MCT cells derived from humans and rodents, as well as canine lymphoma cells, responded poorly to GC. However, there were also some variations in responsiveness to GC treatment among canine MCT cell lines used in this study. Using real-time polymerase chain reaction and Western blot analysis, we elucidated the relationship between GR expression and responsiveness to GC in canine MCT cells. Furthermore, to assess the involvement of GR expression in GC sensitivity in vivo, clinical investigations were conducted on dogs with cutaneous MCT. Written informed consent was obtained from owners, and the affected dogs were treated with prednisolone (0.5-2.0 mg kg(-1)day(-1), administered orally) 1 or 2 weeks prior to the surgical removal of the tumors. Tumor volume was measured according to WHO criteria both before and after prednisolone treatment, and the GC sensitivity of each MCT was determined on the basis of the reduction in tumor volume. Of the 15 dogs with MCT, 11 responded to treatment with prednisolone completely or partially, whereas 4 dogs showed no response. Examination of clinical samples obtained by surgical removal revealed that GR expression levels were significantly lower in GC-resistant MCT tissues than in GC-sensitive MCT tissues. Thus, these results strongly indicate that GR expression may contribute to GC sensitivity in canine MCT.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908058     DOI: 10.1016/j.vetimm.2011.08.013

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

3.  Long-term in-vitro glucocorticoid treatment induces glucocorticoid resistance in canine mast cell tumors.

Authors:  Akira Matsuda
Journal:  Can J Vet Res       Date:  2021-10       Impact factor: 1.310

4.  Intercellular interactions between mast cells and stromal fibroblasts obtained from canine cutaneous mast cell tumours.

Authors:  Lidia H Pulz; Yonara G Cordeiro; Greice C Huete; Karine G Cadrobbi; Arina L Rochetti; Pedro L P Xavier; Adriana Tomoko Nishiya; Silvio Henrique de Freitas; Heidge Fukumasu; Ricardo F Strefezzi
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.